Annemiek Broijl

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 922 citations · Full text

Hematological Malignancy, Radiation Oncology, Medicine +9

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Pieter Sonneveld, Meletios Α. Dimopoulos, Mario Boccadoro et al. · New England Journal of Medicine · 2023 · 435 citations · Full text

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

Evangelos Terpos, Martina Kleber, Monika Engelhardt et al. · Haematologica · 2015 · 391 citations · Full text

Bone Disease, Hematological Malignancy, Zoledronic Acid +14

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç et al. · The Lancet Haematology · 2020 · 377 citations · Full text

Hematological Malignancy, Transplantation, Marrow Transplantation +9

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

María‐Victoria Mateos, Katja Weisel, Valerio De Stefano et al. · Leukemia · 2022 · 225 citations · Full text

Relapsed/refractory Mm, Cancer Management, Immunology +18